The Martinsried-based company 4SC AG, which develops small molecules as agents against cancer and autoimmune diseases, today presented positive clinical data on the annual meeting of the International Liver Cancer Association (ILCA) in Berlin. The presented results are from a phase II clinical trial of Resminostat as a second-line combination therapy with Sorafenib in patients with advanced liver cancer (HCC). With 8.0 months, median overall survival achieved the highest value in comparable HCC second-line treatment studies. In comparison, Sorafenib alone achieved 5.2 months in its approval study. There is currently no approved second-line treatment for patients who suffer a tumour progression under Sorafenib.
In June 2012, progression-free survival data were already presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. After 12 weeks of treatment, the combination therapy reached a progression-free survival (PFSR) of 70% and a median progression-free survival of 4.7 months - one of the highest values of PFS that were reported from clinical studies of second-line treatments of advanced liver cancer.
4SC is seeking a partner for the phase III approval study, which is to be started in the middle of next year. But the partnering should not too difficult on the basis of the good data. The stock market already approved with a rise of 6 percent.